After swearing off startups post a $300 million exit, Karan Bajaj is back with Complement 1, a healthtech venture offering personalised coaching for cancer patients. But this isn’t just a pivot, it’s a whole new playbook.

This time, it’s personal: Bajaj’s mother had cancer, and he says this is the product he wishes she had.

Built for the American market, Complement 1 is taking a B2B route, targeting insurers, employers, and cancer centres. But early traction has been tough. Unlike edtech, healthcare demands more than just hustle. We look at whether Bajaj’s old playbook still works in a world where good intentions must meet rigorous standards and sustainable business models.

Tune in. 

Want to attend The Ken’s next event—How AI is Breaking and Remaking the Way Products are Built?
🎟️ Join us in person or on the livestream—tickets here